Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President
15 February 2023 - 12:30AM
Business Wire
AditxtScore™ continued driving revenue growth in 2022 by
adding to its expanding customer base of large physician networks,
healthcare systems, independent laboratories, and
employer-sponsored programs.
Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an
innovation company developing and commercializing technologies with
a focus on monitoring and modulating the immune system, today
announces the formation of a U.S.-based wholly- owned subsidiary,
Pearsanta, Inc. (“Pearsanta”), to accelerate the growth of Aditxt’s
second program, AditxtScore™, through future strategic revenue and
growth-oriented transactions.
Anthony Voorhies, currently the head of the AditxtScore™
division, will serve as President of Pearsanta. Mr. Voorhies has
over 20 years of clinical diagnostics and healthtech industry
experience. He previously held executive roles with multiple
private and public healthcare companies and has commercialized a
broad range of diagnostic tools, biomarkers, and FDA-cleared
medical devices for early stage and established profitable
companies. Under Mr. Voorhies’ leadership, the AditxtScore™
division has successfully grown from inception to commercialization
and into revenues in just under two years.
“Pearsanta is well positioned for growth in 2023,” said Mr.
Voorhies. “Pearsanta’s focus is on expanding our innovation
platforms through a diversified product offering and pipeline while
driving revenue growth from reimbursement and cash channels.
Pearsanta will also focus on enhancing operational capabilities and
efficiencies, through automation and new delivery systems to
rapidly scale our business and fulfill a growing market demand for
personalized and precise medicine.”
Pearsanta will be headquartered at AditxtScore’s™ existing
immune monitoring center, a 25,000-square-foot CLIA-certified,
CAP-accredited facility in Richmond’s downtown biotech park which
employs a robust and talented team of scientists and laboratory
personnel. Pearsanta will focus on the continued commercialization
of AditxtScore™, a proprietary platform designed to provide a
personalized profile of the immune system which the Company
believes is key to unlocking the potential of precision
medicine.
“The formation of Pearsanta demonstrates Aditxt’s commitment to
its mission and business model of ‘Making Promising Innovations
Possible,’” said Amro Albanna, co-founder, chairman, and CEO of
Aditxt. “This is our second subsidiary to launch, following the
formation of Adimune™, Inc. earlier this year. We look forward to
creating many more exciting opportunities such as these for
Aditxt’s shareholders.”
About Aditxt
Aditxt is an innovation company developing and commercializing
technologies focused on monitoring and modulating the immune
system. Aditxt’s immune monitoring technologies are designed to
provide a personalized immune profile. Aditxt’s immune modulating
technologies, currently preclinical, are being developed to retrain
the immune system to induce tolerance to address rejection of
transplanted organs, autoimmune diseases, and allergies.
For more information, visit the company’s websites at
www.Aditxt.com and www.AditxtScore.com.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company's intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company's ongoing and planned product and business development;
the Company's intellectual property position; the Company's ability
to develop commercial functions; expectations regarding product
launch and revenue; the Company's results of operations, cash
needs, spending, financial condition, liquidity, prospects, growth
and strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as market and other conditions and those risks
more fully discussed in the section titled "Risk Factors" in the
Company's most recent Annual Report on Form 10-K, as well as
discussions of potential risks, uncertainties, and other important
factors in the Company's other filings with the Securities and
Exchange Commission. All such statements speak only as of the date
made, and the Company undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230214005369/en/
Media and Investor Relations Contact: ir@aditxt.com
www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2023 to Apr 2024